Loading stock data…
$28.40+0.15 (+0.53%)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Celldex Therapeutics, Inc. in the Healthcare sector is trading at $28.40 with a market capitalization of $3.0B. Wall Street consensus targets $63.07 (14 analysts), implying a +122.1% move over the next 12 months. The stock is currently 37% below its 52-week high of $45.14, remaining 12.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22,000↑ | $15,000↓ | $121,000 | $0↓ | $730,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$80.62M↑ | -$84.44M↑ | -$87.15M↓ | -$73.62M↓ | -$63.86M |
| Net Income | -$73.50M↑ | -$78.69M↑ | -$81.32M↓ | -$67.04M↓ | -$56.60M |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific ant...